DrugPatentWatch Database Preview
Details for Patent: 6,673,838
» See Plans and Pricing
Which drugs does patent 6,673,838 protect, and when does it expire?
Patent 6,673,838 protects PRISTIQ and is included in one NDA.
This patent has forty-six patent family members in thirty-one countries.
Summary for Patent: 6,673,838
| Title: | Succinate salt of O-desmethyl-venlafaxine |
| Abstract: | A novel salt of O-desmethyl venlafaxine is provided, O-desmethylvenlafaxine succinate. Pharmaceutical compositions, dosage forms and methods of use are also provided. |
| Inventor(s): | Hadfield; Anthony F. (Nanuet, NY), Shah; Syed M. (East Hanover, NJ), Winkley; Michael W. (Campbell Hall, NY), Sutherland; Karen W. (New City, NY), Provost; James A. (Waltham Chase, GB), Park; Aeri (West Lafayette, IN), Shipplett; Rex A. (Wolcott, IN), Russell; Brenton W. (West Lafayette, IN), Weber; Beat T. (Zofingen, CH) |
| Assignee: | Wyeth (Madison, NJ) |
| Application Number: | 10/073,743 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 6,673,838 |
|
Patent Claim Types: see list of patent claims | Compound; Composition; Dosage form; Formulation; Use; |
Drugs Protected by US Patent 6,673,838
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pf Prism Cv | PRISTIQ | desvenlafaxine succinate | TABLET, EXTENDED RELEASE;ORAL | 021992-003 | Aug 20, 2014 | AB | RX | Yes | No | Start Trial | Start Trial | Y | FOR THE APPROVED USES AND CONDITIONS OF USE, INCLUDING DEPRESSION | Start Trial | ||
| Pf Prism Cv | PRISTIQ | desvenlafaxine succinate | TABLET, EXTENDED RELEASE;ORAL | 021992-003 | Aug 20, 2014 | AB | RX | Yes | No | Start Trial | Start Trial | Y | MAINTENANCE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD) | Start Trial | ||
| Pf Prism Cv | PRISTIQ | desvenlafaxine succinate | TABLET, EXTENDED RELEASE;ORAL | 021992-001 | Feb 29, 2008 | AB | RX | Yes | Yes | Start Trial | Start Trial | Y | FOR THE APPROVED USES AND CONDITIONS OF USE, INCLUDING DEPRESSION | Start Trial | ||
| Pf Prism Cv | PRISTIQ | desvenlafaxine succinate | TABLET, EXTENDED RELEASE;ORAL | 021992-001 | Feb 29, 2008 | AB | RX | Yes | Yes | Start Trial | Start Trial | Y | MAINTENANCE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD) | Start Trial | ||
| Pf Prism Cv | PRISTIQ | desvenlafaxine succinate | TABLET, EXTENDED RELEASE;ORAL | 021992-002 | Feb 29, 2008 | AB | RX | Yes | Yes | Start Trial | Start Trial | Y | MAINTENANCE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD) | Start Trial | ||
| Pf Prism Cv | PRISTIQ | desvenlafaxine succinate | TABLET, EXTENDED RELEASE;ORAL | 021992-002 | Feb 29, 2008 | AB | RX | Yes | Yes | Start Trial | Start Trial | Y | FOR THE APPROVED USES AND CONDITIONS OF USE, INCLUDING DEPRESSION | Start Trial | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 6,673,838
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Argentina | 032671 | Start Trial | |||
| Argentina | 082076 | Start Trial | |||
| Austria | 369330 | Start Trial | |||
| Australia | 2002250058 | Start Trial | |||
| Brazil | 0207157 | Start Trial | |||
| Canada | 2436668 | Start Trial | |||
| Canada | 2666611 | Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
